New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
05:40 EDTPSTIPreclinical results for PLX-PAD cells in tendon injury presented at AAOS meeting
Pluristem Therapeutics announced that Dr. Scott Rodeo of New York's Hospital for Special Surgery presented his research findings in a scientific poster titled, "Use of Human Placental-Derived Adherent Stromal Cells Improves Tendon Healing in a Preclinical Model of Tendon Injury," at the American Academy of Orthopedic Surgeons', or AAOS, Annual Meeting. At the AAOS meeting, Dr. Rodeo's poster presentation concluded that: placental-expanded cell therapy appeared to have an early beneficial effect on tendon healing following collagenase injury in this preclinical model; since these cells are immunoprivileged and are expanded ex vivo, its potential for "off-the-shelf" use is attractive relative to existing cell-based therapies; and additional preclinical studies are necessary to understand how these cells may affect tendon repair.
News For PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
05:38 EDTPSTIPluristem says new data shows PLX cells regulate immune system
Pluristem Therapeutics announced the publication of a scientific study regarding PLacental expanded, or PLX, cells in the prominent peer-reviewed journal Stem Cells. The paper, titled "Mesenchymal stromal cells prevent allostimulation in vivo and control checkpoints of Th1 priming: migration of human DC to lymph nodes and NK cell activation", describes the findings of a recent mechanism of action study conducted by independent scientists at the Berlin-Brandenburg Center for Regenerative Therapy at Charité - University Medicine Berlin. The paper was co-authored by scientists from the Charité and Pluristem. The study demonstrated mechanisms by which PLX cells and other mesenchymal stromal cells, or MSC, influence the immune system in order to modulate immune reactions and to prevent immune reactions against the cells when they are administered as an off-the-shelf product. It was demonstrated in vitro that MSC, and in particular PLX cells, control the induction of an immune response at several points. The main target for MSC and PLX cells in this process are dendritic cells, which are the key player in inducing a T-cell immune response. Moreover, in vivo data from patients suffering from critical limb ischemia who were treated with PLX cells in a phase I/II study confirmed that HLA-unmatched PLX cells did not provoke an immune response in immunocompetent patients. These findings confirm the feasibility of using PLX cells in an off-the-shelf manner, and explain the mechanisms that make this possible.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use